Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CorMedix Inc stock logo
CRMD
CorMedix
$11.64
+0.4%
$12.52
$3.61
$17.43
$788.12M1.581.34 million shs1.08 million shs
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
$2.47
-5.4%
$3.10
$1.80
$7.93
$108.33M0.17264,632 shs603,783 shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.77
-1.6%
$6.25
$2.21
$19.71
$622.74M0.451.54 million shs499,121 shs
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$2.40
-1.2%
$2.50
$1.05
$3.31
$525.92M0.972.92 million shs726,725 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CorMedix Inc stock logo
CRMD
CorMedix
0.00%-6.88%-5.98%+98.63%+181.84%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.00%+11.26%-12.41%-26.92%+246,999,900.00%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
0.00%-10.01%+86.49%+79.61%-14.49%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.00%+0.84%-13.98%+96.72%+11.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CorMedix Inc stock logo
CRMD
CorMedix
2.5934 of 5 stars
4.41.00.00.02.50.00.6
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
1.2971 of 5 stars
3.70.00.00.01.00.00.0
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.5962 of 5 stars
4.51.00.00.01.15.00.6
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.3912 of 5 stars
4.51.00.00.03.03.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CorMedix Inc stock logo
CRMD
CorMedix
2.88
Moderate Buy$17.1447.28% Upside
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
3.40
Buy$12.67412.82% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.5099.66% Upside
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.00
Buy$8.20241.67% Upside

Current Analyst Ratings Breakdown

Latest HURA, CRMD, PHAT, and TSHA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/1/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/30/2025
CorMedix Inc stock logo
CRMD
CorMedix
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$20.00
6/24/2025
CorMedix Inc stock logo
CRMD
CorMedix
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $20.00
6/23/2025
CorMedix Inc stock logo
CRMD
CorMedix
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00
6/23/2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
Brookline Capital Management
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/20/2025
CorMedix Inc stock logo
CRMD
CorMedix
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$13.00 ➝ $17.00
6/10/2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CorMedix Inc stock logo
CRMD
CorMedix
$43.47M18.16N/AN/A$1.40 per share8.31
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/A$0.34 per shareN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$55.25M11.07N/AN/A($3.71) per share-2.36
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
$8.33M61.85N/AN/A$0.35 per share6.86
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CorMedix Inc stock logo
CRMD
CorMedix
-$17.93M$0.2252.9112.38N/A20.81%22.57%17.02%8/13/2025 (Estimated)
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$21.68MN/A0.00N/AN/A291.69%122.09%N/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/6/2025 (Estimated)
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$89.30M-$0.34N/AN/AN/A-1,201.08%-104.93%-50.09%8/11/2025 (Estimated)

Latest HURA, CRMD, PHAT, and TSHA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
-$0.13-$0.15-$0.02-$0.15N/AN/A
5/15/2025Q1 2025
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
-$0.08-$0.08N/A-$0.08$1.48 million$2.30 million
5/6/2025Q1 2025
CorMedix Inc stock logo
CRMD
CorMedix
$0.25$0.30+$0.05$0.30$38.90 million$39.08 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CorMedix Inc stock logo
CRMD
CorMedix
N/AN/AN/AN/AN/A
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CorMedix Inc stock logo
CRMD
CorMedix
N/A
4.21
3.99
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A
3.00
3.00
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
3.58
3.54
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
0.77
5.35
5.35

Institutional Ownership

CompanyInstitutional Ownership
CorMedix Inc stock logo
CRMD
CorMedix
34.18%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.62%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
77.70%

Insider Ownership

CompanyInsider Ownership
CorMedix Inc stock logo
CRMD
CorMedix
5.30%
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
0.20%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
23.00%
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
3.78%
CompanyEmployeesShares OutstandingFree FloatOptionable
CorMedix Inc stock logo
CRMD
CorMedix
3067.82 million64.23 millionOptionable
TuHURA Biosciences, Inc. stock logo
HURA
TuHURA Biosciences
N/A43.68 million43.59 millionN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.81 million53.76 millionOptionable
Taysha Gene Therapies, Inc. stock logo
TSHA
Taysha Gene Therapies
180214.66 million206.55 millionOptionable

Recent News About These Companies

Cantor Fitzgerald Estimates TSHA FY2026 Earnings

New MarketBeat Followers Over Time

Media Sentiment Over Time

CorMedix stock logo

CorMedix NASDAQ:CRMD

$11.64 +0.05 (+0.43%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$11.62 -0.02 (-0.13%)
As of 07/3/2025 04:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

TuHURA Biosciences stock logo

TuHURA Biosciences NASDAQ:HURA

$2.47 -0.14 (-5.36%)
Closing price 07/3/2025 03:52 PM Eastern
Extended Trading
$2.49 +0.02 (+0.81%)
As of 07/3/2025 04:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$8.76 -0.15 (-1.63%)
Closing price 07/3/2025 03:47 PM Eastern
Extended Trading
$8.87 +0.10 (+1.20%)
As of 07/3/2025 04:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Taysha Gene Therapies stock logo

Taysha Gene Therapies NASDAQ:TSHA

$2.40 -0.03 (-1.23%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$2.48 +0.08 (+3.13%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.